Evidence map›Paper›PMID 24622320›Full record

ReviewThe lancet. Diabetes & endocrinology2013

SGLT inhibitors in management of diabetes.

Abd A Tahrani, Anthony H Barnett, Clifford J Bailey

Erratum issued Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in The lancet. Diabetes & endocrinology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT02798744 (SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation), which is not on this map. Cited by 143 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
143citing papers in PubMed, 10 pooled it
15.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02798744 phase4completedstarted 2016, after this paper: background citation

SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation: A Randomised Double-blind Placebo-controlled Trial (The SEESAW Study)

Ran2016Enrolled68Registered outcomes15Posted comparisons0ConditionsDiabetes Mellitus, Type 2Armsdiet, empagliflozin, Placebo
PMID 23398530PMID 24948511PMID 24463448PMID 22238392PMID 24722494PMID 23963895PMID 23906415PMID 24929430PMID 24463454PMID 22029981PMID 2305711PMID 24735709other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

143 citing papers in PubMed, 10 syntheses or guidelines pooled it, 330 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Fracture Risk After Initiation of Use of Canagliflozin: A Cohort Study.Annals of internal medicine · 2019 · on this map
    Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Effects of the SGLT2 inhibitor dapagliflozin in early Alzheimer's disease: A randomized controlled trial.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

83 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Abd A TahraniCentre of Endocrinology, Diabetes and Metabolism, School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, UK; Department of Diabetes and Endocrinology, Heart of England NHS Foundation Trust, Birmingham, UK.
Anthony H BarnettCentre of Endocrinology, Diabetes and Metabolism, School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, UK; Department of Diabetes and Endocrinology, Heart of England NHS Foundation Trust, Birmingham, UK.
Clifford J BaileySchool of Life and Health Sciences, Aston University, Birmingham, UK. Electronic address: c.j.bailey@aston.ac.uk.
University of Birmingham · GBAston University · GB

Funding

Department of Health RTF/01/094
6 · The paper itself

Abstract

The two main sodium-glucose cotransporters (SGLTs), SGLT1 and SGLT2, provide new therapeutic targets to reduce hyperglycaemia in patients with diabetes. SGLT1 enables the small intestine to absorb glucose and contributes to the reabsorption of glucose filtered by the kidney. SGLT2 is responsible for reabsorption of most of the glucose filtered by the kidney. Inhibitors with varying specificities for these transporters (eg, dapagliflozin, canagliflozin, and empagliflozin) can slow the rate of intestinal glucose absorption and increase the renal elimination of glucose into the urine. Results of randomised clinical trials have shown the blood glucose-lowering efficacy of SGLT inhibitors in type 2 diabetes when administered as monotherapy or in addition to other glucose-lowering therapies including insulin. Increased renal glucose elimination also assists weight loss and could help to reduce blood pressure. Effective SGLT2 inhibition needs adequate glomerular filtration and might increase risk of urinary tract and genital infection, and excessive inhibition of SGLT1 can cause gastro-intestinal symptoms. However, the insulin-independent mechanism of action of SGLT inhibitors seems to offer durable glucose-lowering efficacy with low risk of clinically significant hypoglycaemia at any stage in the natural history of type 2 diabetes. SGLT inhibition might also be considered in conjunction with insulin therapy in type 1 diabetes.

Indexed as

Diabetes Mellitus, Type 2GlucoseHumansHypoglycemic AgentsIntestinal MucosaKidneySodium-Glucose Transport ProteinsGlucoseHypoglycemic AgentsSodium-Glucose Transport Proteins

Identifiers

PMID24622320
OpenAlexW2151345870

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.